Search Results 1891-1900 of 4054 for Solid
Recipient of a solid organ or allogenic transplant who is currently receiving systemic immunosuppressive therapy. Any condition possibly affecting oral drug ...
... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. A Study to Evaluate Maximizing Anti-PD-1 Therapy By Monitoring T Cell Responses In Melanoma ...
... solid tumor malignancies. Oncology. 2014; 86 (5-6):271-8 Epub 2014 June 04. View PubMed; White WM, Garrett AT, Craici IM, Wagner SJ, Fitz-Gibbon PD, Butters ...
A Study of the Safety, Tolerability, Drug/Body Interactions, Biological and Clinical Activity of MSB0011359C (M7824) in Metastatic or Locally Advanced Solid ...
... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined ...
... solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and ...
... solid tumors curatively treated by surgery alone or surgery plus radiotherapy with no evidence of disease continuously for > 5 years. Any active disease ...
... solid organ transplant program. The program delivers world-class care to critically ill patients battling end-stage lung disease who need a lung transplant ...
A2B101-101: Obtaining Solid Tumor Tissue from Subjects Having Surgical Resection for Certain Tumor Types and Leukapheresis for CAR T-cell Therapy Manufacturing.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!